Companies Dominating the Intranasal Corticosteroids Landscape
- AstraZeneca PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sunovion Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Services, Inc.
- GSK plc
- Sanofi S.A.
- Ivax Pharmaceuticals, Inc.
- OptiNose US, Inc.
- Chattem Chemicals, Inc.
- Intersect ENT Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of intranasal corticosteroids is estimated at USD 7.44 billion.
Intranasal Corticosteroids Market size was valued at USD 7.13 billion in 2024 and is likely to cross USD 13.61 billion by 2037, registering more than 5.1% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is predicted to account for largest revenue share by 2037, on account of higher prevalence of type 1 diabetes, rheumatoid arthritis, and other types of sclerosis.
The major players in the market are AstraZeneca PLC, Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., GSK plc, Sanofi S.A., Ivax Pharmaceuticals, Inc., OptiNose US, Inc., Chattem Chemicals, Inc., and Intersect ENT Inc.
